Literature DB >> 30578254

Mechanisms of immune escape after allogeneic hematopoietic cell transplantation.

Robert Zeiser1, Luca Vago2,3.   

Abstract

Relapse of the original disease is a major cause of death after allogeneic hematopoietic cell transplantation for acute leukemias. There is growing evidence that relapses may be explained not only by resistance to chemotherapy but also by the escape of tumor cells from the control of the allogeneic immune response. Mechanisms of immune evasion can involve abrogation of leukemia cell recognition due to loss of HLA genes, immunosuppression by immune-checkpoint ligand expression, production of anti-inflammatory factors, release of metabolically active enzymes, loss of proinflammatory cytokine production, and acquisition of novel driver mutations that promote leukemia outgrowth. These mechanisms, and therapeutic targeting of immune escape, will be discussed. We divide the evidence in support of immune-escape mechanisms into animal studies, human laboratory studies, and human clinical experience. A better understanding of the molecular pathways connected to immune escape and relapse may help to improve our therapeutic armamentarium against acute myeloid leukemia relapse.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 30578254     DOI: 10.1182/blood-2018-10-846824

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  Clonal evolution and immune evasion in posttransplantation relapses.

Authors:  Luca Vago
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 2.  T cell optimization for graft-versus-leukemia responses.

Authors:  Melinda A Biernacki; Vipul S Sheth; Marie Bleakley
Journal:  JCI Insight       Date:  2020-05-07

3.  Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.

Authors:  Mahmoud R Gaballa; Pinaki Banerjee; Denái R Milton; Xianli Jiang; Christina Ganesh; Sajad Khazal; Vandana Nandivada; Sanjida Islam; Mecit Kaplan; May Daher; Rafet Basar; Amin Alousi; Rohtesh Mehta; Gheath Alatrash; Issa Khouri; Betul Oran; David Marin; Uday Popat; Amanda Olson; Priti Tewari; Nitin Jain; Elias Jabbour; Farhad Ravandi; Hagop Kantarjian; Ken Chen; Richard Champlin; Elizabeth Shpall; Katayoun Rezvani; Partow Kebriaei
Journal:  Blood       Date:  2022-03-24       Impact factor: 22.113

4.  Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.

Authors:  Xiang-Yu Zhao; Xing-Xing Yu; Zheng-Li Xu; Xun-Hong Cao; Ming-Rui Huo; Xiao-Su Zhao; Ying-Jun Chang; Yu Wang; Xiao-Hui Zhang; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Blood Adv       Date:  2019-12-23

Review 5.  Immune escape and immunotherapy of acute myeloid leukemia.

Authors:  Luca Vago; Ivana Gojo
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 6.  Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD.

Authors:  Bruce R Blazar; Geoffrey R Hill; William J Murphy
Journal:  Nat Rev Clin Oncol       Date:  2020-04-20       Impact factor: 66.675

Review 7.  Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.

Authors:  Joseph C Rimando; Matthew J Christopher; Michael P Rettig; John F DiPersio
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

Review 8.  The Role of Immune Checkpoints after Cellular Therapy.

Authors:  Friederike Schmitz; Dominik Wolf; Tobias A W Holderried
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

9.  Galectin-9 and PSMB8 overexpression predict unfavorable prognosis in patients with AML.

Authors:  Yongping Zhang; Song Xue; Qi Hao; Fuhong Liu; Wenqiu Huang; Jingbo Wang
Journal:  J Cancer       Date:  2021-05-19       Impact factor: 4.207

Review 10.  Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Wei Shi; Weiwei Jin; Linghui Xia; Yu Hu
Journal:  Acta Pharm Sin B       Date:  2020-06-30       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.